Ripped Femme Fat Metabolism Support Supplement
Ripped Femme Fat Metabolism Support Supplement, NPN 80068991: natural health product licensed in Canada. Medicinal ingredients: Olea europaea, 3-hydroxyméthylindole, L-Carnitine, Capsicum annuum.
If this product were sold in France
- Legal conditions
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
annexe III, partie B (règlement (UE) 2022/2340). Regulation (EC) No 1925/2006, latest consolidated version, retrieved 21 October 2026, source updated 26 November 2025.
- Legal conditions
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Olea europaea Source : Feuille Extraction ratio : 4:1 Dry plant equivalent : 60 mg Potency : 16 % Oleuropein | 15 mg | Not calculated |
| 3-hydroxyméthylindole Source : Indole-3-carbinol | 100 mg | Not calculated |
| L-Carnitine Source : L-tartrate de carnitine | 100 mg | Not calculated |
| Capsicum annuum Source : Fruit | 200 mg | Not calculated |
| 1,3,7-triméthylxanthine Source : Caféine | 200 mg | Not calculated |
| Camellia sinensis Source : Feuille Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 364 mg Potency : 50 % Epigallocatechin 3-gallate | 91 mg | Not calculated |
| Vitamine B12 Source : Méthylcobalamine | 2 mcg | 4 µg |
Non-medicinal ingredients
Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Capsule | 2 Tous les jours |
Uses authorised in Canada
Source of/Provides antioxidants. Helps to support/promote healthy estrogen metabolism/balance. Helps support fat metabolism. Workout support/supplement. Capsicum annum is traditionally used in Herbal Medicine to help support peripheral circulation. Helps to temporarily promote alertness and wakefulness, and to enhance cognitive performance when used occasionally. Workout supplement. Athletic support. Helps (temporarily) to relieve fatigue, to promote endurance, and to enhance motor performance when used occasionally. Helps the body to metabolize carbohydrates, fats, and proteins. Helps to form red blood cells.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Cautions and Warnings
If you are taking any medication or natural health products, consult a health care practitioner prior to use. If you are attempting to conceive, consult a health care practitioner prior to use. If you have symptoms of low estrogen (such as joint pain, mood changes, changes in libido, hot flashes, night sweats, vaginal dryness or irregular menstruations), consult a healthcare practitioner prior to use. If you develop liver-related symptoms (e.g. yellowing of the skin, abdominal pain, jaundice) or symptoms of low estrogen, discontinue use and consult a health care practitioner. To exclude the diagnosis of a serious cause of hormonal imbalance, consult a health care practitioner prior to use. If symptoms persist or worsen, consult a health care practitioner. If you have a liver disease, a kidney disease, or a seizure disorder, consult a healthcare practitioner prior to use. Keep out of the reach of children. If overdose or accidental ingestion occurs, call a Poison Control Center immediately. If you have stomach ulcers or inflammation, consult a health care practitioner prior to use. Ensure to drink enough fluid before, during, and after exercise. Consult a health care practitioner prior to use if you are taking lithium. Consult a health care practitioner prior to use if you have glaucoma, and/or detrusor instability (overactive bladder syndrome). Consumption with natural health products (e.g. bitter orange extract, synephrine, octopamine, ephedra) or other drugs (e.g. ephedrine) which increase blood pressure is not recommended. Consumption with other caffeine-containing products (e.g. medications, coffee, tea, colas, cocoa, guarana, maté) is not recommended. This product is not intended as a substitute for sleep. Consult a health care practitioner if you are of childbearing age. Consult a health care practitioner prior to use if you have a liver disorder or develop symptoms of liver trouble (such as abdominal pain, dark urine or jaundice). Consult a health care practitioner prior to use if you have an iron deficiency. If you are taking other diuretics, consult a health care practitioner prior to use. Caffeine has been shown to reduce blood flow to the heart muscle during exercise which might lead to cardiovascular complications such as chest pain, spasm and irregular heartbeat even in healthy individuals. If those symptoms occur discontinue use and consult a health care practitioner. Diuretic effect may occur. If you have a liver disorder, consult a health care practitioner prior to use. Stop use if you develop symptoms of liver trouble such as yellowing of the skin/eyes (jaundice), stomach pain, dark urine, sweating, nausea, unusual tiredness and/or loss of appetite and consult a health care practitioner.
Product record
- Licence holder
- Kaleidoscope Health Inc.
- NPN or DIN-HM
- 80068991
- Status
- Active licence
- Licence date
- 28 April 2016
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
Source
Official Health Canada record, licence 80068991
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Olea europaea
Read the warning, when it applies and the studies cited
OLIVE LEAF - OLEA EUROPAEA
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you pregnant or breastfeeding (EMA 2017).
Sources cited by Health Canada (1)
- EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder (EMA 2017).
Sources cited by Health Canada (1)
- EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other diuretics (EMA 2017).
Sources cited by Health Canada (1)
- EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf
Known adverse reactions
Condition of application: All products except those making a diuretic claim.
When using this product diuretic effect may occur.
- L-Carnitine
Read the warning, when it applies and the studies cited
L-CARNITINE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a seizure disorder (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.
- Capsicum annuum
Read the warning, when it applies and the studies cited
CAYENNE - CAPSICUM ANNUUM Oral
Cautions and warnings
Condition of application: All products.
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).
Sources cited by Health Canada (2)
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Condition of application: Digestion; Peripheral circulation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical
Cautions and warnings
Condition of application: All products.
For external use only (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Known adverse reactions
Condition of application: All products.
Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).
Sources cited by Health Canada (5)
- APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
- Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
- McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Randomised trial
- Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Systematic review
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Ripped Femme Fat Metabolism Support Supplement (Kaleidoscope Health Inc.): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80068991-ripped-femme-fat-metabolism-support-supplement, updated 28 April 2016.